A randomized, placebo-controlled, double-blind, multi-dose escalation phase IIa study was conducted to evaluate the safety, tolerability, pharmacokinetics, and efficacy of oral HPP737 in patients with moderate to severe COPD.
Latest Information Update: 08 Jun 2026
At a glance
- Drugs Prifemilast - Newsoara Biopharma (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions; Proof of concept; Therapeutic Use
Most Recent Events
- 24 Feb 2021 New trial record